CAR T and Bispecific Agents in Hematologic Malignancies
Expert perspectives and strategic insights on new and relevant clinical advances of CAR T and bispecific agents in hematologic malignancies
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Ibrahim Aldoss, MD
City of Hope, Duarte, CA
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
Krishna Komanduri, MD
Sylvester Comprehensive Cancer Center, Miami, FL
Julio Chavez, MD
H Lee Moffitt Cancer Center, Tampa, FL
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University, Atlanta, GA
Noopur Raje, MD
Mass General Cancer Center, Boston, MA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- CAR T Cells in Leukemias (including ALL/AML)
- CAR T Cells in DLBCL
- CAR T Cells in MCL and FL
- CAR T Cells in MM
- Bispecific Agents in Leukemias
- Bispecific Agents in B-NHL
- Bispecific Agents in Myeloma
- Managing Toxicity of Bispecific Agents and CAR T Cells
